The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep WTP a big fall today such as the vagaries of AIM but similar to here in that a nice consolidation after a very big recent rise ready for the next leg up.
I know Bermuda.
Totally different business models based on history etc and all SCLP science is to be proved up and monetised which is great.SCLP strategic plan is again different and an evolving one but an eg of what can be done re monetisation core or non core.
For eg SCLP does not have any redistribution of reserves so would not be a pathway for them practically or strategically
Yeah it seems with the Glycans ..... the plan was monetise them ASAP then it seems the money was not going to be much considering the potential they hold .... so redmiles money meant go forth and add that value CAR T ADC etc.... Avidimab maybe different it seems there is still potential deal/s or 'research collabs' that could come there... however again there Covidity means scancell get a chance to trial it so the value on success would be many x.... we are still in H1 so in theory still on track forever piece of the puzzle to click in it's place but time is getting on with no news...
one thing is for sure RG is not retweeting CEPI anymore now that can mean nothing is coming or talks are on .... I'd think talks are on that does not mean we get funding news soon or at all but it doesn't mean we don't .... certainly main thing is getting into trial ASAP
Interestingly the market reaction to Open Orphans news is mixed to say the least.
Probably Glycans mAbs and Avidimab were considered non-core until Redmile's second investment.
Ivy,
Not sure they've ever had any non-core assets
Morning.
The Moditope situation has been explained by others but as per Cleanerworlds original point regarding OO these are non core assets which have been well signposted and part of the strategic future to reward SH by monetising non core assets.
SCLP have never gone down this route as part of their business model
David Evans has given a very candid account of the events surrounding the potential spin out of Moditope back in 2012/3 and it needs to be viewed in the context of the biotech. environment in the UK at that time.
Seed funding for biotech was relatively easy to come by but there was a significant gap when it came to follow-on funding - the so called valley of death. The argument for spinning out Moditope was that it would be much easier to secure seed funding to progress preclinical development. However, even though ImmunoBody had produced fantastic clinical trial results, cancer vaccines were a no-go area for big pharma - they simply couldn't secure any commercial interest and ImmunoBody was at the edge of that valley of death. The argument against spinning out Moditope was that it would be against the interests of existing Scancell shareholders who would be left holding stock in a company with an underfunded product in a 'cold area' of cancer research.
With hindsight, it was a fortuitous decision as we have now come full circle and now it's ImmunoBody that is driving funding and attracting investors and cancer vaccines are about to become hot again. I'm not sure it would have survived if Moditope had been spun off into a separate company and that would have been a tragedy. Incidentally, an excellent example of the benefit of having independent non-execs on the board when it comes to protecting the interests of shareholders.
ha there is all sorts of history here we don't know too much about ... always seems SCIB1 had a pharma interested in it right from the beginning and everyone understood on trial success it would be sold...it never happened that was the eve of the AGM of doom!.... Can speculate that pharma was GSK who just had a disaster with their very expensive DNA vaccine trial meaning there was no way they were going to take on another DNA cancer vax.... if so not savvy of scancell to have put its hopes in one basket... anyways whole new chapter now :)
Reminds of us of Scancell way back when Moditope was a serendipity discovery...................buy 1 get 1 free, lol.
Crumbs
i hope they didn't have the money because if they did maybe at least one of the dilutive cash rasings could have been avoided.
AB snap..... I believe DE felt it would be too confusing and for Lindy to have her IP in 2 separate companies would not be good also for us in scancell having the crown jewels taken away would not be great either
In the early days when moditope was discovered there were plans among some on the BOD RG in particular to spin it out and create a new company just around that platform I'm not sure about this but think they had a potential money backer for that but DE flatly refused and kept all the IP together he won... since then of course Glycans and AvidiMab have come in house too... And I would not be supposed if on the success the new peptide delivery would come in house too... and on real real success reckon Lindy would be bringing in all kinds of talents and their IPs into scancell......... sadly we are still at a stage of being unable to turn great IP into heaps of money
I think there was discussion about spinning out Moditope a long time ago and a previous chairman had said that it was decided against.
Might be wrong though.
A fair point Cleanerworld, immumobody, moditope, Avidimab could be very easily be standalone spin outs IMO.
Maybe Scancell/Redmile and more importantly a big pharma want the whole shebang?
scancell aren't spinning out IP they are bringing it in ....they just can't manage then to monetise it lol
https://www.lse.co.uk/rns/ORPH/potential-demerger-of-certain-non-core-assets-abi77m6qf6r22wk.html
Open Orham RNS Interesting approach to their IP . find the paragraph that caught my eye :
"The Board believes that to maximise shareholder value that the Development IP Assets are best developed separately from the core services business. Furthermore, such a spin-out transaction could provide the opportunity to secure separate financial resources for these assets, to enable accelerated development of these assets and achievement of commercial milestones. A spin-out transaction would also allow Shareholders to benefit from both the value of the development assets and the standalone value of the core services business, as they progress through their own key milestones."